Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding insider transactions rather than a financial performance report.
Material Changes
The filing discloses a specific transaction involving a connected person:
- Connected Person: Dr K Slaoui (connected person of Dr M M Slaoui).
- Transaction Date: April 24, 2015.
- Transaction Type: Increase in the notional allocation of GSK American Depositary Shares (ADSs).
- Quantity: 5 ADSs.
- Price: $46.59 per ADS.
- Context: The increase resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the identity of Dr K Slaoui and the nature of the connection to Dr M M Slaoui.
- Confirm the impact of the 401K plan revaluation on the notional allocation of ADSs.
- Note that this filing does not contain financial performance data for the period.